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Lynch syndrome
Colorectal cancer (CRC) is the most common malignancy within the European Union and ranks second to lung cancer as a cause of cancer-related mortality [1]. CRC results from both genetic and environmental factors. The most common genetic susceptibility for CRC is Lynch syndrome (LS), formerly known as hereditary non-polyposis colorectal cancer (HNPCC). LS accounts for approximately 3% of all
CRCs [2, 3] , and also for 2% of all endometrial cancers [4] . The burden of LS is considerably greater than these percentages imply, as the cancers are diagnosed at a young age and synchronous or metachronous malignancies occur in 30% of the patients [5, 6] . [7] [8] [9] [10] [11] [12] [13] [14] [15] , and the definitive diagnosis is currently made by identification of an inactivating germline mutation in one of the MMR genes MLH1, MSH2, MSH6 or PMS2 [16] . Early detection of LS is of great importance, particularly in pre-symptomatic mutation carriers, since colonoscopic surveillance has proven to reduce CRC morbidity and mortality by 65-70% [17] [18] [19] 
LS is characterized by a high lifetime risk for the development of CRC (20-70%), endometrial cancer (15-70%) and other extracolonic cancers (Ͻ15%)
. These extra-colonic malignancies include carcinomas of the small intestine, stomach, pancreas and biliary tract, ovarium, brain, upper urinary tract and skin. LS is caused by germline mutations in mismatch repair (MMR) genes
Identification of patients at risk for Lynch syndrome
Different models and strategies have been developed to identify patients with LS. In 1990, the Amsterdam Criteria I were developed to provide a basis for uniformity in collaborative studies to find the disease-causing gene (Table 1 ) [21] . These criteria were designed to be highly specific at the expense of the sensitivity [3, 22] . They were criticized because extra-colonic tumours were not taken into account, thereby excluding classical LS families. Therefore, the Amsterdam Criteria II were established in 1999 (Table 2 ) [23] . However, many families with the syndrome (i.e. mutation carriers) do not meet these criteria [24] , usually because these families are too small or there is a late onset of the disease. In addition, obtaining a thorough family history is difficult in clinical practice [25] and patients may have limited knowledge of their family history [26, 27] .
In 1997, the Bethesda Guidelines were published to select patients whose tumours should be analysed for molecular features associated with LS, i.e. microsatellite instability (MSI) , to identify potential mutation carriers ( [67] in numerous investigated LS tumours [68] [69] [70] [71] [72] [73] [74] [75] 76] . These results indicate that BRAF mutations are closely correlated with MLH1 methylation in sporadic CRCs [69-72, 76, 77] . Therefore, BRAF mutation status can be used to identify sporadic microsatellite unstable tumours, although it has been demonstrated that determination of hypermethylation of the MLH1 gene promoter is more sensitive to detect sporadic MSI tumours [69] .
Fig. 2 MSI. A schematic microsatellite is indicated (poly A track). When the tumour cells have an intact MMR system the size of the microsatellite will be the same in DNA isolated from normal (N) and from tumour (T) cells: microsatellite stable (MSS) tumour. In case of a defect in MMR the
In addition to sporadic forms of MLH1 promoter hypermethylation, germline epimutations of MLH1 (soma-wide mono-allelic hypermethylation of the gene promoter) have also been reported [78] [79] [80] [81] [82] [83] [84] [85] [81, 82] .
Besides germline MLH1 hypermethylation, a new mechanism of germline MSH2 hypermethylation has recently been discovered [87] . Ligtenberg [104, 105] . [102, 106] (Fig. 3) . Similarly, absence of MSH2 due to MSH2 mutations results in absence of MSH6 (Fig. 3) , since MSH6 and PMS2 will disintegrate without their obligatory partners MSH2 and MLH1, respectively. A mutation in either PMS2 or MSH6 does not lead to loss of MLH1 and MSH2 protein, respectively (Fig. 3) , because of the formation of other heterodimers than MLH1-PMS2 and MSH2-MSH6. MLH1 can for instance dimerize with either MLH3 or PMS1 [108, 109] and MSH2 can also bind to MSH3 [110] (Fig. 5) . 
The limitations of the Bethesda panel have lead to the development of a pentaplex panel, which comprises five quasi-monomorphic mononucleotide repeats (see below). This panel shows less variation in size among different ethnic populations and has been shown to be superior to the Bethesda panel for the detection of MSI-H tumours
Table 6 Immunohistochemical expression patterns associated with MMR-gene mutations
MMR-gene mutation
MLH1 MSH2 MSH6 PMS2
Protein expression
MLH1 Ϫ* ϩ ϩ ϩ MSH2 ϩ Ϫ ϩ ϩ MSH6 ϩ Ϫ Ϫ ϩ PMS2 Ϫ ϩ ϩ Ϫ
* Absent MLH1 protein expression can be associated with either MLH1 germline mutations as well as epigenetic MLH1 silencing by promoter methylation. ϩ ϭ present nuclear protein expression in tumour cells (as well as in normal cells). Ϫ ϭ absent nuclear protein expression in tumour cells (and present staining in normal cells, thus serving as internal positive control).
Although MSI can be reliably detected even when DNA is isolated from a tissue fragment composed of only 10% neoplastic cells (unpublished data), tumour DNA is isolated preferably from a tissue fragment with a high percentage (Ͼ70%) of tumour cells. DNA isolated from tissue with a high percentage of tumour cells can also be used for reliable additional investigations (BRAF mutation and MLH1 hypermethylation). In the case of an adenoma the fragment with the highest grade of dysplasia should be used for DNA isolation. For isolation of normal DNA a tissue fragment composed of normal cells, preferably from the normal epithelial counterpart of the tumour (e.g. normal colorectal or normal endometrial mucosa), is used to circumvent heterogeneity problems that can be caused by mosaicism (e.g. mosaic MLH1 promoter germline hypermethylation or MSH2 promoter hypermethylation only in Epcam expressing cells
Immunohistochemistry
Our method of immunohistochemistry was described in detail previously [112] (Fig. 3) . [114] 
MLH1 promoter hypermethylation assay
In case of absent MLH1 expression in tumour cells, the methylation status of the MLH1 promoter can be determined by different methods such as methylation-specific PCR [113] and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)
BRAF mutation analysis
BRAF alterations of mutational hotspot codon V600 are determined by bi-directional cycle sequencing of PCR-amplified fragments. PCR amplification is performed by M13-tailed forward primer 5Ј-TGT AAA ACG ACG GCC AGT AAA CTC TTC ATA ATG CTT GCT CTG -3Ј and M13-tailed reverse primer 5Ј-CAG
Limitations of molecular analyses
Over the last decade, the diagnostics of LS have improved considerably. Nevertheless, there still remain some limitations that need to be addressed. It has to be taken into account that the described procedures provide information on the chance that a [113, 120, 121] [65, 76, 80, 122, [124] [125] [126] [127] [128] [129] . However, only one study evaluated the proximal promoter region (region D) associated with gene silencing in 55 CRCs and endometrial cancers of MLH1 germline mutation carriers [129] . [65, 76, 80, 122, [124] [125] [126] [127] [128] .
There are some other points of concern in the molecular diagnostics of LS. First, the value of MSI testing and immunohistochemistry in other LS-related tumours than CRC is largely unknown [130] . In endometrial tumours, the second most common malignancy in LS, MSI can escape detection by the occurrence of only subtle shifts in the size of the markers [131] . Therefore, MSI analysis in endometrial cancers is performed with patient matched normal DNA as the reference, and molecular prescreening has been found feasible [4, 132, 133] (Fig. 6B, (Fig. 4) 
